Approval · Notice of Compliance 30620 · 2023
ANAFRANIL: Notice of Compliance 30620
Issued May 3, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30620
- Date
- May 3, 2023
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Updates to the Product Monograph (PM) and Conversion of the PM to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ANAFRANIL | Not yet assigned | — |
Medicinal ingredients
- CLOMIPRAMINE HCL 10 MG per TAB
- CLOMIPRAMINE HCL 25 MG per TAB
- CLOMIPRAMINE HCL 50 MG per TAB